Sarcoidosis
| Agente | Año | Tipo de estudio | Pacientes (n) | TR (n) | Casos adversos | Recaída | Muertes |
|---|---|---|---|---|---|---|---|
| INFLIXIMAB | 2006 |
A |
91 |
91 |
80 |
0 |
1 |
| Total | 91 |
91 |
80 |
0 |
1 |
||
| % | 100 |
87,9120879 |
|||||
| INFLIXIMAB | 2004 |
C |
5 |
5 |
0 |
2 |
0 |
2005 |
C |
10 |
9 |
3 |
1 |
0 |
|
2005 |
C |
9 |
9 |
1 |
0 |
0 |
|
2006 |
C |
12 |
12 |
1 |
4 |
1 |
|
| Total | 36 |
35 |
5 |
7 |
1 |
||
| % | 97,222222 |
13,8888889 |
|||||
| INFLIXIMAB | 2001 |
D |
3 |
3 |
0 |
0 |
0 |
2001 |
D |
1 |
1 |
1 |
0 |
0 |
|
2002 |
D |
1 |
1 |
0 |
0 |
0 |
|
2003 |
D |
1 |
1 |
0 |
0 |
0 |
|
2003 |
D |
1 |
1 |
0 |
0 |
0 |
|
2003 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2004 |
D |
1 |
1 |
1 |
0 |
1 |
|
2004 |
D |
1 |
1 |
0 |
0 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
2 |
2 |
1 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
1 |
0 |
0 |
|
| Total | 27 |
27 |
4 |
0 |
1 |
||
| % | 100 |
14,8148148 |
|||||
| ETANERCEPT | 2005 |
A |
9 |
0 |
2 |
0 |
0 |
| Total | 9 |
0 |
2 |
0 |
0 |
||
| % | 0 |
22,2222222 |
|||||
| ETANERCEPT | 2003 |
C |
17 |
5 |
2 |
0 |
0 |
| Total | 17 |
5 |
2 |
0 |
0 |
||
| % | 29,411765 |
11,7647059 |
|||||
| ETANERCEPT | 2003 |
D |
1 |
1 |
1 |
0 |
0 |
2005 |
D |
1 |
1 |
0 |
1 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
0 |
0 |
0 |
0 |
|
| Total | 4 |
3 |
1 |
1 |
0 |
||
| % | 75 |
25 |
|||||
| ADALIMUMAB | 2005 |
D |
1 |
1 |
0 |
0 |
0 |
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2006 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 3 |
3 |
0 |
0 |
0 |
||
| RITUXIMAB | 2005 |
D |
1 |
1 |
0 |
1 |
0 |
| Total | 1 |
1 |
0 |
1 |
0 |